CAI
Caris Life Sciences·NASDAQ
--
--(--)
--
--(--)
5.54 / 10
Netural
Analyst consensus leans bullish (25% Strong Buy, 50% Buy) but recent performance is mixed, with weighted rating 3.23 and pessimistic market expectations. Fund‑flow metrics are good (7.86), showing inflows in Small‑, Medium‑ and Large‑size trades despite overall negative trend.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
25%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-27
InstitutionBaird
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for CAI?
- CAI holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.54/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
